Iloperidone (Fanapt) vs Risperidone (Uzedy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Partial signal

NCT00254202 · Phase 3 · completed

This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).

Next expected readout: November 2027 · NCT06961968 (registry estimate)

Reported efficacy

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)

Result source: NCT00254202

Risperidone (Uzedy)

Marketed by Teva Pharmaceutical Industries and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT03503318 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 544 participants assigned to placebo, monthly TV-46000, or every-two-month TV-46000. The hard clinical primary endpoint was time to impending relapse, and it was statistically significantly favorable for both monthly treatment (13/183 vs 53/181; p<0.0001) and every-two-month treatment (23/179 vs 53/181; p<0.0001).

Reported efficacy

Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181 (met)

Result source: NCT03503318

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointIloperidone (Fanapt)Risperidone (Uzedy)
PANSS total, change-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
—Not posted · NCT00159770
CGI-S, change—Trial running · NCT06961968—Not posted · NCT00159770
PANSS response—Trial running · NCT06961968—Not posted · NCT00159770
PSP, change—Trial running · NCT06961968—Not posted · NCT00159770
Relapse (% of patients)—Trial running · NCT069619687.1% vs 29.3%−22.2 vs placeboq1m · n 183NCT03503318
7 other results
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · primary NCT03503318
  • 0.1% vs 0.3% q1m · wk 24 · n 183 · Phase 3 · secondary NCT03503318
  • 0.1% vs 0.3% q2m · wk 24 · n 179 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 13.3% vs 29.3% q2m · n 180 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · secondary NCT03503318

PANSS total, change

Iloperidone (Fanapt)
-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
Risperidone (Uzedy)
—Not posted · NCT00159770

CGI-S, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Risperidone (Uzedy)
—Not posted · NCT00159770

PANSS response

Iloperidone (Fanapt)
—Trial running · NCT06961968
Risperidone (Uzedy)
—Not posted · NCT00159770

PSP, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Risperidone (Uzedy)
—Not posted · NCT00159770

Relapse (% of patients)

Iloperidone (Fanapt)
—Trial running · NCT06961968
Risperidone (Uzedy)
7.1% vs 29.3%−22.2 vs placeboq1m · n 183NCT03503318
7 other results
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · primary NCT03503318
  • 0.1% vs 0.3% q1m · wk 24 · n 183 · Phase 3 · secondary NCT03503318
  • 0.1% vs 0.3% q2m · wk 24 · n 179 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 13.3% vs 29.3% q2m · n 180 · Phase 3 · secondary NCT03503318
  • 7.1% vs 29.3% q1m · n 183 · Phase 3 · secondary NCT03503318
  • 12.8% vs 29.3% q2m · n 179 · Phase 3 · secondary NCT03503318
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Iloperidone (Fanapt): 4 of 4 rows · Risperidone (Uzedy): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIloperidone (Fanapt)Risperidone (Uzedy)
Dropout rate
34.6%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
51.3%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
30.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
31.5%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
18.8%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.5%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
13.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
21.3%q1mb
NCT03503318 · Phase 3 · monotherapy
show 3 more results
22.2%q2m
NCT03503318 · Phase 3 · monotherapy
22.4%q1m
NCT03893825 · Phase 3 · monotherapy
24.7%q2m
NCT03893825 · Phase 3 · monotherapy
Discontinued due to AEs
—a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
14.5%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
10.4%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
15%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
2.2%q1mb
NCT03503318 · Phase 3 · monotherapy
show 3 more results
1.1%q2m
NCT03503318 · Phase 3 · monotherapy
0%q1m
NCT03893825 · Phase 3 · monotherapy
1.2%q2m
NCT03893825 · Phase 3 · monotherapy
Serious AEs
0.7%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
—Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
4%Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
2.7%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
7.1%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
4.4%q1mb
NCT03503318 · Phase 3 · monotherapy
show 3 more results
5.6%q2m
NCT03503318 · Phase 3 · monotherapy
4.7%q1m
NCT03893825 · Phase 3 · monotherapy
6.8%q2m
NCT03893825 · Phase 3 · monotherapy
Most frequent reported AEs
a
headache 20.3% (placebo 19.7%)
dizziness 17% (placebo 7.5%)
sedation 12.7% (placebo 8.2%)
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 18 more results
dizziness 11.6% (placebo 2.7%)
somnolence 8.3% (placebo 0%)
dry mouth 6.8% (placebo 0%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dizziness 2.6% (placebo 2.7%)
headache 2% (placebo 3.3%)
insomnia 2% (placebo 4.7%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dry mouth 17.9%
dizziness 17.5%
somnolence 14.2%
NCT01207414 · Phase 4 · registry result, not featured evidence
dizziness 22.3%
dry mouth 20.8%
insomnia 9.6%
NCT01207414 · Phase 4 · registry result, not featured evidence
625 mg
injection site pain 66.7%
injection site induration 60%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
625 mg
headache 20%
nasal congestion 20%
anxiety 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
injection site pain 60%
injection site induration 26.7%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
nasal congestion 33.3%
constipation 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
back pain 7.1%
constipation 7.1%
headache 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
insomnia 20%
headache 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
constipation 14.3%
headache 14.3%
anxiety 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
headache 33.3%
insomnia 33.3%
dyspepsia 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
injection site pain 53.3%
headache 26.7%
nasal congestion 26.7%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
nasal congestion 40%
headache 26.7%
oropharyngeal pain 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
pruritus 50%
throat irritation 50%
upper respiratory tract infection 50%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
constipation 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
blood creatine phosphokinase increased 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
dizziness 50%
headache 50%
agitation 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
q1mb
injection site nodule 6.6% (placebo 3.4%)
insomnia 6.6% (placebo 5.6%)
injection site pruritus 5.5% (placebo 2.2%)
NCT03503318 · Phase 3 · monotherapy
show 3 more results
q2m
injection site nodule 7.2% (placebo 3.4%)
weight increased 7.2% (placebo 3.4%)
injection site pain 6.7% (placebo 6.1%)
NCT03503318 · Phase 3 · monotherapy
q1m
injection site pain 5.2%
injection site nodule 1.7%
NCT03893825 · Phase 3 · monotherapy
q2m
injection site nodule 5.6%
injection site pain 4.3%
NCT03893825 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Iloperidone (Fanapt)

PANSS Total -12 vs -7.1 placebo score @ 4wk
absolute change · score
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 1 more result
1.1 vs 12.4 placebo score @ 26wk
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
Time to Relapse NA vs 3.25 placebo months @ 26wk
time to event · months
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S 3 vs 3.6 placebo score @ 26wk
absolute value · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
SDS -0.2 vs 1.8 placebo score @ 26wk
absolute change · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-C 2.826 score @ 12wk
absolute value · score
No placebo or comparator arm
NCT01207414 · Phase 4 · registry result, not featured evidence
show 1 more result
2.824 score @ 12wk
NCT01207414 · Phase 4 · registry result, not featured evidence
CGI-S -0.8 score @ 12wk
absolute change · score
No placebo or comparator arm
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.8 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence

Risperidone (Uzedy)

Relapse 7.1% (n=183) vs 29.3% (n=181) placeboq1m
event count · % of participants
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
show 7 more results
12.8% (n=179) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
7.1% (n=183) vs 29.3% (n=181) placebo*q1m
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
13.3% (n=180) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 24 Participants as posted
0.07% (n=183) vs 0.28% (n=181) placebo @ 24wkq1m
NCT03503318 · Phase 3 · monotherapy
0.11% (n=179) vs 0.28% (n=181) placebo @ 24wkq2m
NCT03503318 · Phase 3 · monotherapy
7.1% (n=183) vs 29.3% (n=181) placebo*q1m
NCT03503318 · Phase 3 · monotherapy · converted to % from 13 Participants as posted
12.8% (n=179) vs 29.3% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
Clinical Remission 21.3% (n=183) vs 16.6% (n=181) placeboq1m
responder rate · % of participants
NCT03503318 · Phase 3 · monotherapy · converted to % from 39 Participants as posted
show 1 more result
23.5% (n=179) vs 16.6% (n=181) placebo*q2m
NCT03503318 · Phase 3 · monotherapy · converted to % from 42 Participants as posted
Relapse 100% (n=1)q2m
event count · % of participants
No placebo or comparator arm
NCT03503318 · Phase 3 · monotherapy · converted to % from 1 Participants as posted
SQLS -4.5 vs 0.9 placebo scoreq1m
absolute change · score
Change at the Endpoint
NCT03503318 · Phase 3 · monotherapy
show 1 more result
-4.1 vs 0.9 placebo scoreq2m
Change at the Endpoint
NCT03503318 · Phase 3 · monotherapy
CDSS -0.3 vs -0.4 placebo scoreq1m
absolute change · score
Change at the End of Treatment
NCT03503318 · Phase 3 · monotherapy
show 1 more result
-0.8 vs -0.4 placebo scoreq2m
Change at the End of Treatment
NCT03503318 · Phase 3 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Risperidone (Uzedy)'s landscape